Genmab正在进行高级会谈,以获得荷兰癌症药商Merus,这可能是其最大的交易,但受有希望的药物结果的驱动。 Genmab is in advanced talks to acquire Dutch cancer drugmaker Merus, potentially its biggest deal yet, driven by promising drug results.

据Bloomberg新闻报导, 丹麦生物制药公司Genmab正在进行先期谈判, 以取得荷兰癌症药物开发商Merus, Danish biopharmaceutical company Genmab is in advanced talks to acquire Dutch cancer drug developer Merus in a deal that could be its largest yet, according to Bloomberg News. 由于其实验性药物petosemtamab与默克的Keytruda联合治疗头癌的有希望的结果, 潜在的收购是在Merus股票表现强的情况下进行的. The potential acquisition comes amid strong stock performance for Merus, fueled by promising results from its experimental drug petosemtamab in combination with Merck’s Keytruda for head and neck cancers. 虽然尚未达成最后协议,而且可能出现其他投标人,但讨论反映了肿瘤药物开发领域的日益巩固。 While no final agreement has been reached and other bidders could emerge, the discussions reflect growing consolidation in the oncology drug development field.